These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 22003288

  • 1. Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.
    Bleecker ER, Siler T, Owen R, Kramer B.
    Int J Chron Obstruct Pulmon Dis; 2011; 6():431-8. PubMed ID: 22003288
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
    Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P.
    Int J Chron Obstruct Pulmon Dis; 2014 Dec; 9():215-28. PubMed ID: 24596459
    [Abstract] [Full Text] [Related]

  • 4. Safety of indacaterol in the treatment of patients with COPD.
    Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B.
    Int J Chron Obstruct Pulmon Dis; 2011 Dec; 6():477-92. PubMed ID: 22003293
    [Abstract] [Full Text] [Related]

  • 5. Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.
    Kim CJ, Yoon HK, Park MJ, Yoo KH, Jung KS, Park JW, Lim SY, Shim JJ, Lee YC, Kim YS, Oh YM, Kim S, Yoo CG.
    Int J Chron Obstruct Pulmon Dis; 2017 Dec; 12():1589-1596. PubMed ID: 28615931
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
    Dahl R, Jadayel D, Alagappan VK, Chen H, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2013 Dec; 8():501-8. PubMed ID: 24159259
    [Abstract] [Full Text] [Related]

  • 7. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
    Kerwin EM, Williams J.
    Ther Adv Respir Dis; 2013 Feb; 7(1):25-37. PubMed ID: 23296242
    [Abstract] [Full Text] [Related]

  • 8. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
    Laforce C, Aumann J, de Teresa Parreño L, Iqbal A, Young D, Owen R, Higgins M, Kramer B, INTEGRAL Study Investigators.
    Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.
    Jiang FM, Liang ZA, Zheng QL, Wang RC, Luo J, Li CT.
    Lung; 2013 Apr; 191(2):135-46. PubMed ID: 23306410
    [Abstract] [Full Text] [Related]

  • 10. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
    Ulrik CS.
    Int J Chron Obstruct Pulmon Dis; 2014 Apr; 9():331-8. PubMed ID: 24729699
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.
    Rhee CK, Park HY, Park JW, Lee JH, Kim TH, Lee SW, Jung JY, Kim S, Hwang YI, Jung KS.
    Trials; 2017 Feb 22; 18(1):80. PubMed ID: 28228162
    [Abstract] [Full Text] [Related]

  • 12. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.
    Respir Med; 2013 Feb 22; 107(2):223-32. PubMed ID: 23219347
    [Abstract] [Full Text] [Related]

  • 13. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.
    Roskell NS, Anzueto A, Hamilton A, Disse B, Becker K.
    Int J Chron Obstruct Pulmon Dis; 2014 Feb 22; 9():813-24. PubMed ID: 25114521
    [Abstract] [Full Text] [Related]

  • 14. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M.
    Pulm Pharmacol Ther; 2007 Feb 22; 20(6):740-9. PubMed ID: 17088091
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
    Rajagopalan K, Bloudek L, Marvel J, Dembek C, Kavati A.
    Int J Chron Obstruct Pulmon Dis; 2018 Feb 22; 13():3867-3877. PubMed ID: 30568438
    [Abstract] [Full Text] [Related]

  • 16. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug 22; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 17. Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients' perceived onset of effect.
    Siler TM, LaForce CF, Kianifard F, Williams J, Spangenthal S.
    Int J Chron Obstruct Pulmon Dis; 2014 Aug 22; 9():919-25. PubMed ID: 25214778
    [Abstract] [Full Text] [Related]

  • 18. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
    Wedzicha JA, Buhl R, Lawrence D, Young D.
    Respir Med; 2015 Jan 22; 109(1):105-11. PubMed ID: 25433954
    [Abstract] [Full Text] [Related]

  • 19. Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial.
    Kato M, Makita H, Uemura K, Fukuchi Y, Hosoe M, Emery C, Higgins M, Kramer B.
    Allergol Int; 2010 Sep 22; 59(3):285-293. PubMed ID: 20567133
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
    Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K, CRYSTAL study investigators.
    Respir Res; 2017 Jul 18; 18(1):140. PubMed ID: 28720132
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.